Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | AKT1 | P31749 | 7/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | APAF1 | O14727 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | TDP2 | O95551 | 1/20 | 0.38 |
| ▸ | NSD2 | O96028 | 1/20 | 0.38 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | GALK1 | P51570 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | PDIA6 | Q15084 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25273095 | 0.81 | MAPT (0.42) | KMT2ATSHRMEN1HSD17B10SMN1; SMN2 | |
| SCHEMBL25626205 | 0.70 | L3MBTL1 (0.50) | KMT2ATSHRMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL20424477 | 0.70 | TP53 (0.50) | SMN1; SMN2AKT1ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL15518325 | 0.68 | AKT1 (0.79) | AKT1PIK3CAPIK3CBPIK3CD | |
| SCHEMBL12476001 | 0.68 | AKT1 (0.56) | AKT1PIK3CAPIK3CBPIK3CD | |
| SCHEMBL12475780 | 0.68 | AKT1 (0.56) | AKT1PIK3CAPIK3CBPIK3CD | |
| SCHEMBL2147106 | 0.65 | ALDH1A1 (0.44) | KMT2ATSHRMEN1HSD17B10ALDH1A1 | |
| SCHEMBL22587289 | 0.64 | KMT2A (0.68) | KMT2ATSHRMEN1HSD17B10SMN1; SMN2 | |
| SCHEMBL2650247 | 0.64 | MAPT (0.78) | SMN1; SMN2ALDH1A1MAPTRAB9A | |
| SCHEMBL22587292 | 0.63 | KMT2A (0.67) | KMT2ATSHRMEN1HSD17B10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4444317-A2 | BICYCLIC HETEROARENES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| US-20230271965-A1 | BICYCLIC HETEROARENES AND METHODS OF THEIR USE | YUMANITY THERAPEUTICS, INC. | 2023-08-31 | — | — | US | disclosed |
| US-20230271965-A1 | BICYCLIC HETEROARENES AND METHODS OF THEIR USE | YUMANITY THERAPEUTICS, INC. | 2023-08-31 | — | — | US | disclosed |
| WO-2023107623-A2 | BICYCLIC HETEROARENES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023107623-A2 | BICYCLIC HETEROARENES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| EP-4161523-A1 | BICYCLIC HETEROARENES AND METHODS OF THEIR USE | Yumanity Therapeutics, Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271965-A1 | BICYCLIC HETEROARENES AND METHODS OF THEIR USE | NLN, GRIN2C, BCHE | KMT2A 2841/4885TSHR 3951/4885MEN1 2915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.